- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Mepolizumab – November 2017
Mepolizumab: Powder for injection 100 mg; Nucala®
Last updated
2 March 2018